STAT's Washington Correspondent John Wilkerson joins us to discuss the first round of drug pricing negotiations under the Inflation Reduction Act, which will wrap up by September 1. We also cover the latest news in the life sciences including the merger of AI drug development companies Recursion Pharmaceuticals and Exscientia, Novo Nordisk's decision to paus ... Show More
Sep 24
The FDA's Overton era, and dispatches from Shanghai
"The Readout LOUD" is going international this week. STAT's Jason Mast joins the podcast from Shanghai, where he's digging into what the rise of Chinese drug development means for the biotech industry. The hosts also speak to colleague Margaret Manto about Heidi Overton, the pres ... Show More
29m 41s
May 2023
Ozempic the Anti-Addiction Drug, Age of Streaming Mergers, & Bezos's Boat
Episode 65: Neal and Toby discuss the increasing buzz around potent weight loss drugs with Pfizer's oral version and Ozempic's anti-addiction side effects. Then, Showtime merges with Paramount+, Max absorbs Discovery+, and Disney+ wants to include Hulu. Are we entering the age of ... Show More
28m 43s
Sep 2023
Pumped-Up Prices, Closed-Door Meeting 9/13/23
<p>We’re following 2 big stories today: CPI & AI. August’s data showed inflation up 3.7% year-over-year. That was hotter than July, but can be blamed on gas prices. Are we really past the inflation threat? We’ll discuss.</p><p>Plus, Elon Musk, Mark Zuckerberg and Bill gates are m ... Show More
43m 38s
May 2025
Fed Decision On Deck… And Novo Nordisk Gears Up To Report 5/6/25
<p>Another key Fed decision on deck, as the recent stock market bounce loses steam. What to expect from Fed Chair Jerome Powell, and what it will mean for the market’s next move. Plus Earnings season in full swing, and Wegovy-maker Novo Nordisk is ready to report. Why one top hea ... Show More
43m 52s